CA2874979A1 - Antigen binding proteins that bind dll-4 - Google Patents

Antigen binding proteins that bind dll-4 Download PDF

Info

Publication number
CA2874979A1
CA2874979A1 CA2874979A CA2874979A CA2874979A1 CA 2874979 A1 CA2874979 A1 CA 2874979A1 CA 2874979 A CA2874979 A CA 2874979A CA 2874979 A CA2874979 A CA 2874979A CA 2874979 A1 CA2874979 A1 CA 2874979A1
Authority
CA
Canada
Prior art keywords
seq
variable domain
dll
antibody
called
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2874979A
Other languages
English (en)
French (fr)
Inventor
Edwige Gros
Yanliang Zhang
Heyue Zhou
Randy GASTWIRT
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sorrento Therapeutics Inc
Original Assignee
Sorrento Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sorrento Therapeutics Inc filed Critical Sorrento Therapeutics Inc
Publication of CA2874979A1 publication Critical patent/CA2874979A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA2874979A 2012-05-31 2013-05-28 Antigen binding proteins that bind dll-4 Abandoned CA2874979A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261654019P 2012-05-31 2012-05-31
US61/654,019 2012-05-31
PCT/US2013/042912 WO2014062245A2 (en) 2012-05-31 2013-05-28 Antigen binding proteins that bind dll-4

Publications (1)

Publication Number Publication Date
CA2874979A1 true CA2874979A1 (en) 2014-04-24

Family

ID=49670535

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2874979A Abandoned CA2874979A1 (en) 2012-05-31 2013-05-28 Antigen binding proteins that bind dll-4

Country Status (7)

Country Link
US (2) US10174107B2 (enExample)
EP (1) EP2855523A4 (enExample)
JP (1) JP2015520172A (enExample)
CN (1) CN104603151A (enExample)
CA (1) CA2874979A1 (enExample)
HK (1) HK1206038A1 (enExample)
WO (1) WO2014062245A2 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8883145B2 (en) 2009-10-16 2014-11-11 Oncomed Pharmaceuticals, Inc. Methods of treatment with DLL4 antagonists and an anti-hypertensive agent
SI3485903T1 (sl) 2011-09-23 2023-02-28 Mereo Biopharma 5, Inc. Sredstva, ki vežejo VEGF/DLL4, in njihove uporabe
WO2014062245A2 (en) 2012-05-31 2014-04-24 Sorrento Therapeutics Inc. Antigen binding proteins that bind dll-4
BR112017000130A2 (pt) 2014-07-11 2018-01-09 Genentech Inc método para atenuar a toxicidade associada à inibição da via de notch e método de tratamento do câncer
US20160176962A1 (en) 2014-10-31 2016-06-23 Oncomed Pharmaceuticals, Inc. Combination Therapy For Treatment Of Disease
CN114853891A (zh) * 2015-07-22 2022-08-05 索伦托药业有限公司 与lag3结合的抗体治疗剂
ES2968074T3 (es) 2015-09-23 2024-05-07 Mereo Biopharma 5 Inc Anticuerpo bi-específico anti-VEGF/DLL4 para su uso en el tratamiento del cáncer de ovario resistente al platino
KR20210095781A (ko) 2020-01-24 2021-08-03 주식회사 에이프릴바이오 항원결합 단편 및 생리활성 이펙터 모이어티로 구성된 융합 컨스트럭트를 포함하는 다중결합항체 및 이를 포함하는 약학조성물

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001268427B2 (en) 2000-06-16 2007-03-29 Glaxosmithkline Intellectual Property Limited Antibodies that immunospecifically bind to blys
IL149820A0 (en) 2002-05-23 2002-11-10 Curetech Ltd Humanized immunomodulatory monoclonal antibodies for the treatment of neoplastic disease or immunodeficiency
US20070244709A1 (en) * 2006-04-17 2007-10-18 Earthworks Systems, Llc Methods of producing and recycling plastic cards
AR061246A1 (es) * 2006-06-06 2008-08-13 Genentech Inc Anticuerpos anti- dill4 y metodos que los usan
HUE028379T2 (en) * 2006-09-29 2016-12-28 Oncomed Pharm Inc Preparations and procedures for the diagnosis and treatment of cancer
RU2448979C2 (ru) * 2006-12-14 2012-04-27 Ридженерон Фармасьютикалз, Инк. Антитела человека к дельта-подобному лиганду-4 человека
CN102264763B (zh) * 2008-09-19 2016-04-27 米迪缪尼有限公司 定向于dll4的抗体及其用途
US8623358B2 (en) * 2009-08-29 2014-01-07 Abbvie Inc. Therapeutic DLL4 binding proteins
WO2014062245A2 (en) 2012-05-31 2014-04-24 Sorrento Therapeutics Inc. Antigen binding proteins that bind dll-4

Also Published As

Publication number Publication date
EP2855523A4 (en) 2016-02-17
US20190169282A1 (en) 2019-06-06
US10174107B2 (en) 2019-01-08
EP2855523A2 (en) 2015-04-08
US10717779B2 (en) 2020-07-21
WO2014062245A3 (en) 2014-10-09
WO2014062245A2 (en) 2014-04-24
JP2015520172A (ja) 2015-07-16
US20130323248A1 (en) 2013-12-05
CN104603151A (zh) 2015-05-06
HK1206038A1 (en) 2015-12-31

Similar Documents

Publication Publication Date Title
AU2022204504B2 (en) Antigen binding proteins that bind PD-L1
US20240190959A1 (en) Antigen Binding Proteins that Bind PD-L1
US11242391B2 (en) Antigen binding proteins that bind PD-1
US10717779B2 (en) Methods for blocking an interaction between notch-1 and delta-like 4 (DLL-4) by administering a DDL-4 antibody
US20200399367A1 (en) Anti-cd47 antibodies and uses thereof
CA2875543A1 (en) Antigen binding proteins that bind igf1r

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20190528